Jasper Therapeutics, Inc. (JSPR)
| Market Cap | 17.71M |
| Revenue (ttm) | n/a |
| Net Income | n/a |
| EPS | n/a |
| Shares Out | 33.27M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 381,305 |
| Open | 0.4900 |
| Previous Close | 0.5010 |
| Day's Range | 0.4755 - 0.5447 |
| 52-Week Range | 0.3151 - 2.6900 |
| Beta | 3.17 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 9, 2026 |
About JSPR
Jasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases. It is advancing a pipeline of medicines, including KP-104, a dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other unmet need nephrology disorders; Briquilimab is an anti-KIT antibody, which has demonstrated clinical results as a conditioning agent for stem cell transplant and mast cell mediated diseases, ... [Read more]
Financial Performance
Financial StatementsNews
Jasper Therapeutics completes enrollment in IgAN cohort of KP104 study
Jasper Therapeutics (JSPR) announced that it has completed enrollment of the IgA nephropathy, or IgAN, cohort of its Phase 2 basket study evaluating vensobafusp alfa, or KP104, a bifunctional biologic...
Jasper Therapeutics Announces Completion of Enrollment in First Cohort of Phase 2 Renal Basket Study Evaluating Vensobafusp Alfa (KP104) in IgA Nephropathy
Initial Stage 1 data evaluating ven s obafusp alfa in IgAN expected by year-end 2026 Announces e xpansion cohort in patients with FSGS , with first patients anticipated to be dosed in first quarter 20...
Jasper Therapeutics files to sell 284.01M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 284.01M shares of common stock. The company is not selling any…
Jasper Therapeutics Registration statement: Registration filing
Jasper Therapeutics filed a registration statement on October 14, 2026, providing details about a securities offering with the SEC.
Jasper Therapeutics resumed with an Outperform at William Blair
William Blair resumed coverage of Jasper Therapeutics (JSPR) with an Outperform rating. The buy rating is based on the potential of Jasper’s bifunctional molecule KP-104 to deliver best-in-class effic...
Jasper Therapeutics Proxy statement: Proxy filing
Jasper Therapeutics filed a proxy statement on October 9, 2026, providing details for shareholder voting and corporate governance matters.
Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants
REDWOOD CITY, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a clinical stage biotechnology company focused on the design and developme...
Jasper Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference
The company, following its merger, now has a robust immunology pipeline with multiple clinical assets, highlighted by vensobafusp's strong phase II PNH data and ongoing renal studies. Well-funded into 2028, it anticipates key data readouts and regulatory milestones over the next year.
Jasper Therapeutics Announces Key Regulatory and Clinical Appointments
Lisa Pitt, Pharm.D., M.S.J. appointed Senior Vice President, Regulatory Affairs Shiguang Liu, M.D.
Jasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
REDWOOD CITY, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical stage biotechnology company focused on the design and development of innovative...
Jasper Therapeutics Proxy statement: Proxy filing
Jasper Therapeutics filed a proxy statement on September 4, 2026, providing details for shareholder voting and corporate governance matters.
Jasper Therapeutics Proxy statement: Proxy filing
Jasper Therapeutics filed a proxy statement on August 24, 2026, providing details for shareholder voting and corporate governance matters.
Jasper Therapeutics initiated with an Overweight at Piper Sandler
Piper Sandler initiated coverage of Jasper Therapeutics (JSPR) with an Overweight rating and $2 price target The company’s lead asset KP-104 simultaneously blocks the alternative pathway and terminal ...
Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Acquisition of Kira Pharmaceuticals closed in July creating a combined company with a robust portfolio of clinical stage assets focused on immunologically-driven disorders
Jasper Therapeutics Quarterly report: Q2 2026
Jasper Therapeutics has published its Q2 2026 quarterly earnings report on August 14, 2026.
Jasper Therapeutics Earnings release: Q2 2026
Jasper Therapeutics released its Q2 2026 earnings on August 14, 2026, summarizing the period's financial results.
Jasper Therapeutics trading resumes
17:45 EDT Jasper Therapeutics (JSPR) trading resumes
Jasper Therapeutics completes acquisition of Kira Pharmaceuticals
Jasper Therapeutics (JSPR) announced that Jasper has completed the acquisition of Kira Pharmaceuticals in an all-stock transaction. The combined company will focus on advancing a consolidated pipeline...
Jasper Therapeutics Announces Merger with Kira Pharmaceuticals
Combined company positioned to advance portfolio of biologic agents designed to improve outcomes in patients with numerous immunologically-driven disorders
Jasper Therapeutics trading halted, news pending
17:10 EDT Jasper Therapeutics (JSPR) trading halted, news pending
Jasper Therapeutics Proxy statement: Proxy filing
Jasper Therapeutics filed a proxy statement on June 15, 2026, providing details for shareholder voting and corporate governance matters.
Jasper Therapeutics Proxy statement: Proxy filing
Jasper Therapeutics filed a proxy statement on June 15, 2026, providing details for shareholder voting and corporate governance matters.
Jasper Therapeutics initiates review of strategic alternatives
Jasper Therapeutics (JSPR) announced that, following an evaluation of current market conditions, its board of directors has decided to initiate a review of strategic alternatives. Strategic alternativ...
Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibod...
Jasper Therapeutics price target lowered to $3 from $4 at RBC Capital
RBC Capital lowered the firm’s price target on Jasper Therapeutics (JSPR) to $3 from $4 and keeps a Sector Perform rating on the shares. The firm continues to believe that…